SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy wit. ...

PresentationDirk ThyeCEO, Chief Medical Officer & Director Greetings, everyone, and welcome to our first ever Investor Day for Quince Therapeutics. My name is Dirk Thye, and I'll be walking you through the beginning elements of our presentation. We've got a full agenda for you today. I'm going to start by giving you an overview of Quince Therapeutics, our technology, our development plans and our key investment highlights. And then I'm going to hand it over to a series of departmental and technical experts ...

In the current session, Bristol-Myers Squibb Inc. (NYSE:BMY) is trading at $45.73, after a 3.58% decrease. Over the past month, the stock decreased by 2.06%, and in the past year, by 15.25%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. How Does Bristol-Myers Squibb P/E Compare to Other Companies?The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical ...

SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achieve’s 2024 E ...

The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer. ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart conditions, hereditary transthyretin-mediated amyloidosis (ATTR-CM) and polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector. ...

阿斯利康股价上涨原因 - 阿斯利康股价本周上涨超过10% [1] - 股价上涨主要原因是辉瑞公司与特朗普政府宣布了一项重大协议 [1] - 阿斯利康自身公布了Enhertu治疗HER2阳性早期乳腺癌临床试验的积极结果 [1] 辉瑞公司与特朗普政府的协议详情 - 辉瑞计划大幅降低其在美国的许多处方药价格 [2] - 辉瑞将投资700亿美元以扩大其在美国国内的业务 [2] - 辉瑞将参与新的TrumpRx网站，帮助消费者寻找折扣药品 [2] - 作为回报，辉瑞将获得三年宽限期，在此期间不受特朗普政府对美国药品进口关税的影响 [3] 阿斯利康可能受益的原因 - 特朗普总统暗示未来可能会有其他与辉瑞类似的协议，阿斯利康作为市值第四大制药公司，很可能效仿辉瑞 [4] - 阿斯利康已宣布计划在美国扩张，承诺投资500亿美元继续在美国增长，包括在弗吉尼亚州进行其历史上最大的制造投资 [5] - 公司有很大机会在未来三年内像辉瑞一样获得关税豁免 [5] 阿斯利康的投资前景 - 公司股票定价合理，远期市盈率约为15倍，并持续实现强劲的盈利增长 [9] - 公司在研发管线方面取得重大进展，最近几个月公布了十多项后期临床研究的积极结果 [9] - 笼罩在整个生物制药行业（包括阿斯利康）的一些不确定性已被消除 [7]